• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Ocular Therapeutix™ Appoints Merilee Raines to Its Board of Directors

    9/22/21 8:00:00 AM ET
    $IDXX
    $OCUL
    $TMDX
    $WTS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IDXX alert in real time by email

    Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the appointment of Merilee Raines to the Company's Board of Directors effective September 20, 2021.

    "We are excited to welcome Merilee to our Board of Directors," said Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix. "Merilee brings a wealth of operational, financial, and business experience to our team. Having started as employee #11 at IDEXX, she helped to drive a multitude of innovative growth strategies and successfully scaled the business from start-up to the multinational it is today. Her guidance and input will be invaluable as we seek to grow Ocular into a strategic leader in the ophthalmology space."

    Ms. Raines brings deep experience as a former public company financial executive having served 28 years with IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing. During her career at IDEXX, Ms. Raines held multiple positions of increasing responsibilities and served as the Company's Executive Vice President and Chief Financial Officer at her retirement in May 2013. Ms. Raines is also an experienced independent board director and currently serves as a member of the Board of Directors of Transmedics Group, Inc. (NASDAQ:TMDX), Watts Water Technologies, Inc. (NYSE:WTS) and Excelitas Technologies Corporation, a private company. She holds a M.B.A. from University of Chicago, an A.B. from Bowdoin College and is a Certified Public Accountant (inactive status).

    "Ocular has successfully leveraged its hydrogel platform to bring an innovative product in DEXTENZA® to market and emerge as a highly-focused ophthalmology company with a pipeline of differentiated products designed to drive long-term growth," said Ms. Raines. "I am pleased to be joining Ocular and the other members of its Board during this exciting period."

    About Ocular Therapeutix, Inc.

    Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Ocular Therapeutix's first commercial drug product, DEXTENZA®, is an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery. Ocular Therapeutix has received a target action date under the Prescription Drug User Fee Act, commonly known as PDUFA, of October 18, 2021, for a supplemental new drug application for DEXTENZA to include an additional indication for the treatment of ocular itching associated with allergic conjunctivitis. Ocular Therapeutix's earlier stage development assets currently in Phase 1 clinical trials include OTX-TKI (axitinib intravitreal implant) for the treatment of wet AMD and other retinal diseases and OTX-TIC (travoprost intracameral implant) for the reduction of intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension. Ocular Therapeutix is currently evaluating OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease and OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease in Phase 2 clinical trials. Ocular Therapeutix's first product, ReSure® Sealant, is an FDA-approved device to prevent wound leaks in corneal incisions following cataract surgery.

    Forward-Looking Statements

    Any statements in this press release about future expectations, plans, and prospects for the Company, including the commercialization of DEXTENZA®, ReSure® Sealant, or any of the Company's product candidates; the commercial launch of, and effectiveness of reimbursement codes for, DEXTENZA; the conduct of post-approval studies of and compliance with related labeling requirements for DEXTENZA and ReSure Sealant; the development and regulatory status of the Company's product candidates, such as the Company's development of and prospects for approvability of DEXTENZA for additional indications including the PDUFA target action date scheduled for October 18, 2021 for allergic conjunctivitis, OTX-CSI for the chronic treatment of dry eye disease, OTX-DED for the short-term treatment of the signs and symptoms of dry eye disease, OTX-TIC for the treatment of primary open-angle glaucoma or ocular hypertension, and OTX-TKI for the treatment of retinal diseases including wet AMD; the ongoing development of the Company's extended-delivery hydrogel depot technology; the size of potential markets for our product candidates; the potential utility of any of the Company's product candidates; the potential benefits and future operations of Company collaborations, including any potential future costs or payments thereunder; projected net product revenue, in-market sales and other financial and operational metrics of DEXTENZA and ReSure Sealant; potential market sizes for indications targeted by the Company's product candidates, if approved; the expected impact of the COVID-19 pandemic on the Company and its operations; the sufficiency of the Company's cash resources and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend", "goal," "may", "might," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company's preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the timing and costs involved in commercializing DEXTENZA, ReSure Sealant or any product candidate that receives regulatory approval, including the conduct of post-approval studies, the ability to retain regulatory approval of DEXTENZA, ReSure Sealant or any product candidate that receives regulatory approval, the ability to maintain and the sufficiency of product, procedure and any other reimbursement codes for DEXTENZA, the initiation, timing, conduct and outcomes of clinical trials, availability of data from clinical trials and expectations for regulatory submissions and approvals, the Company's ability to enter into and perform its obligations under collaborations and the performance of its collaborators under such collaborations, the Company's scientific approach and general development progress, the availability or commercial potential of the Company's product candidates, the Company's ability to generate its projected net product revenue and in-market sales on the timeline expected, if at all, the sufficiency of cash resources, the Company's existing indebtedness, the ability of the Company's creditors to accelerate the maturity of such indebtedness upon the occurrence of certain events of default, the severity and duration of the COVID-19 pandemic including its effect on the Company's and relevant regulatory authorities' operations, any additional financing needs and other factors discussed in the "Risk Factors" section contained in the Company's quarterly and annual reports on file with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views as of the date of this press release. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this press release.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20210922005315/en/

    Get the next $IDXX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IDXX
    $OCUL
    $TMDX
    $WTS

    CompanyDatePrice TargetRatingAnalyst
    Watts Water Technologies Inc.
    $WTS
    4/16/2025$229.00Hold → Buy
    Stifel
    Ocular Therapeutix Inc.
    $OCUL
    4/8/2025Outperform
    William Blair
    Ocular Therapeutix Inc.
    $OCUL
    3/18/2025$17.00Outperform
    RBC Capital Mkts
    Ocular Therapeutix Inc.
    $OCUL
    3/11/2025$15.00Buy
    Needham
    Watts Water Technologies Inc.
    $WTS
    12/17/2024$240.00Hold
    Deutsche Bank
    TransMedics Group Inc.
    $TMDX
    12/17/2024$116.00 → $75.00Overweight → Neutral
    Analyst
    IDEXX Laboratories Inc.
    $IDXX
    12/2/2024$500.00Outperform
    Leerink Partners
    TransMedics Group Inc.
    $TMDX
    11/22/2024Buy → Hold
    Needham
    More analyst ratings

    $IDXX
    $OCUL
    $TMDX
    $WTS
    Financials

    Live finance-specific insights

    See more
    • TransMedics Reports First Quarter 2025 Financial Results

      ANDOVER, Mass., May 8, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2025. Recent Highlights Total revenue of $143.5 million in the first quarter of 2025, a 48% increase compared to the first quarter of 2024Generated net income of $25.7 million or $0.70 per fully diluted share in the first quarter of 2025Raising full year 2025 revenue guidance to $565

      5/8/25 4:05:00 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Watts Water Technologies Reports First Quarter 2025 Results

      Sales of $558 million, down 2% on a reported and organic basis Operating margin of 15.7%, down 120 bps; adjusted operating margin of 19.0%, up 80 bps Diluted EPS of $2.21, up 2%; adjusted diluted EPS of $2.37, up 2% Announced 21% increase in quarterly dividend payments to $0.52 per share Maintaining full year 2025 organic sales and adjusted operating margin outlook Note changes in performance are relative to first quarter 2024 Watts Water Technologies, Inc. (NYSE:WTS) – through its subsidiaries, one of the world's leading manufacturers and providers of plumbing, heating and water quality products and solutions – today announced results for the first quarter of 2025. Chief Execu

      5/7/25 4:35:00 PM ET
      $WTS
      Metal Fabrications
      Industrials
    • Watts Water Technologies, Inc. Declares Quarterly Dividend

      Watts Water Technologies, Inc. (NYSE:WTS) today declared that the Corporation will pay a quarterly dividend of fifty-two cents ($0.52) per share on each outstanding share of the Company's Class A Common Stock and Class B Common Stock, said dividend to be paid on June 13, 2025 to stockholders of record at the close of business on May 30, 2025. Watts Water Technologies, Inc., through its family of companies, is a global manufacturer headquartered in the USA that provides one of the broadest plumbing, heating, and water quality product lines in the world. Watts Water companies and brands offer innovative plumbing, heating, and water quality solutions to control the efficiency, safety, and qua

      5/5/25 5:00:00 PM ET
      $WTS
      Metal Fabrications
      Industrials

    $IDXX
    $OCUL
    $TMDX
    $WTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Watts Water Tech. upgraded by Stifel with a new price target

      Stifel upgraded Watts Water Tech. from Hold to Buy and set a new price target of $229.00

      4/16/25 9:03:50 AM ET
      $WTS
      Metal Fabrications
      Industrials
    • William Blair initiated coverage on Ocular Therapeutix

      William Blair initiated coverage of Ocular Therapeutix with a rating of Outperform

      4/8/25 9:29:59 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital Mkts initiated coverage on Ocular Therapeutix with a new price target

      RBC Capital Mkts initiated coverage of Ocular Therapeutix with a rating of Outperform and set a new price target of $17.00

      3/18/25 7:53:57 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IDXX
    $OCUL
    $TMDX
    $WTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Vandebroek Sophie V. converted options into 262 shares, increasing direct ownership by 29% to 1,167 units (SEC Form 4)

      4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)

      5/8/25 7:01:50 PM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Szostak M Anne converted options into 262 shares (SEC Form 4)

      4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)

      5/8/25 7:01:38 PM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Kingsley Lawrence D converted options into 346 shares, increasing direct ownership by 4% to 9,229 units (SEC Form 4)

      4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)

      5/8/25 7:01:17 PM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $IDXX
    $OCUL
    $TMDX
    $WTS
    SEC Filings

    See more
    • SEC Form 10-Q filed by TransMedics Group Inc.

      10-Q - TransMedics Group, Inc. (0001756262) (Filer)

      5/8/25 4:15:56 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • TransMedics Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - TransMedics Group, Inc. (0001756262) (Filer)

      5/8/25 4:05:28 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 10-Q filed by Watts Water Technologies Inc.

      10-Q - WATTS WATER TECHNOLOGIES INC (0000795403) (Filer)

      5/8/25 10:18:09 AM ET
      $WTS
      Metal Fabrications
      Industrials

    $IDXX
    $OCUL
    $TMDX
    $WTS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • TransMedics Reports First Quarter 2025 Financial Results

      ANDOVER, Mass., May 8, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2025. Recent Highlights Total revenue of $143.5 million in the first quarter of 2025, a 48% increase compared to the first quarter of 2024Generated net income of $25.7 million or $0.70 per fully diluted share in the first quarter of 2025Raising full year 2025 revenue guidance to $565

      5/8/25 4:05:00 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Watts Water Technologies Reports First Quarter 2025 Results

      Sales of $558 million, down 2% on a reported and organic basis Operating margin of 15.7%, down 120 bps; adjusted operating margin of 19.0%, up 80 bps Diluted EPS of $2.21, up 2%; adjusted diluted EPS of $2.37, up 2% Announced 21% increase in quarterly dividend payments to $0.52 per share Maintaining full year 2025 organic sales and adjusted operating margin outlook Note changes in performance are relative to first quarter 2024 Watts Water Technologies, Inc. (NYSE:WTS) – through its subsidiaries, one of the world's leading manufacturers and providers of plumbing, heating and water quality products and solutions – today announced results for the first quarter of 2025. Chief Execu

      5/7/25 4:35:00 PM ET
      $WTS
      Metal Fabrications
      Industrials
    • Watts Water Technologies, Inc. Declares Quarterly Dividend

      Watts Water Technologies, Inc. (NYSE:WTS) today declared that the Corporation will pay a quarterly dividend of fifty-two cents ($0.52) per share on each outstanding share of the Company's Class A Common Stock and Class B Common Stock, said dividend to be paid on June 13, 2025 to stockholders of record at the close of business on May 30, 2025. Watts Water Technologies, Inc., through its family of companies, is a global manufacturer headquartered in the USA that provides one of the broadest plumbing, heating, and water quality product lines in the world. Watts Water companies and brands offer innovative plumbing, heating, and water quality solutions to control the efficiency, safety, and qua

      5/5/25 5:00:00 PM ET
      $WTS
      Metal Fabrications
      Industrials

    $IDXX
    $OCUL
    $TMDX
    $WTS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Ocular Therapeutix Inc.

      SC 13G/A - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

      11/14/24 5:49:38 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Ocular Therapeutix Inc.

      SC 13G - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

      11/14/24 9:37:26 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Ocular Therapeutix Inc.

      SC 13G/A - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

      11/12/24 4:49:23 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IDXX
    $OCUL
    $TMDX
    $WTS
    Leadership Updates

    Live Leadership Updates

    See more
    • TransMedics Appoints Gerardo Hernandez as Chief Financial Officer and Provides Updated 2024 Financial Outlook

      ANDOVER, Mass., Dec. 2, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the appointment of Mr. Gerardo Hernandez as the Company's Chief Financial Officer, effective December 2, 2024. In this role, Mr. Hernandez joins the TransMedics executive leadership team, succeeding Mr. Stephen Gordon. To enable a smooth transition, Mr. Gordon will remain a non-executive employee of the Company until March 31, 2025, before serving as a non-employee senior advisor to the Company focusing on national transplant stakeholder engagem

      12/2/24 4:05:00 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • The Ensign Group Set to Join S&P MidCap 400; Curbline Properties & TransMedics Group to Join S&P SmallCap 600

      NEW YORK, Sept. 26, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 and S&P MidCap 400: S&P SmallCap 600 constituent The Ensign Group Inc. (NASD: ENSG) will replace Southwestern Energy Co. (NYSE:SWN) in the S&P MidCap 400 and TransMedics Group, Inc. (NASD: TMDX) will replace The Ensign Group in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, October 1.  S&P MidCap 400 constituent Chesapeake Energy Corp. (NASD: CHK) is acquiring Southwestern Energy in a deal expected to be completed October 1.Curbline Properties Corp. (NYSE:CURB) will be added to the S&P SmallCap 600 effective prior to the open of trading on Tuesda

      9/26/24 6:04:00 PM ET
      $CCRN
      $CHK
      $ENSG
      $SITC
      Professional Services
      Consumer Discretionary
      Oil & Gas Production
      Energy
    • Ocular Therapeutix® to Host Investor Day on June 13, 2024

      Company to highlight corporate strategy, clinical data, and development plans for AXPAXLI™ in wet AMD and NPDR Event to feature prominent retinal disease experts Baruch D. Kuppermann, MD, PhD (University of California, Irvine) and Dilsher S. Dhoot, MD (California Retina Consultants) In-person event with virtual access to take place on June 13, 2024, at 2:00 PM ET BEDFORD, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company"))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD

      6/5/24 7:30:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IDXX
    $OCUL
    $TMDX
    $WTS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Summer Road Llc bought $7,000,000 worth of shares (930,851 units at $7.52) (SEC Form 4)

      4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

      2/27/24 4:43:51 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Summer Road Llc bought $4,999,998 worth of shares (1,538,461 units at $3.25) (SEC Form 4)

      4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

      12/18/23 4:52:33 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care